Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 713.8
2 343
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Caplin Point Laboratories Ltd
NSE:CAPLIPOINT
|
138.8B INR |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.9B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
213.9B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -204 400% |
| 30th Percentile | 3.3% |
| Median | 7.3% |
| 70th Percentile | 13.3% |
| Max | 567 451.5% |
Other Profitability Ratios
Caplin Point Laboratories Ltd
Glance View
Nestled in the bustling business corridors of Chennai, Caplin Point Laboratories Ltd. emerged quietly yet resolutely from its humble origins in 1990. With foresight and strategic maneuvering, the company embarked on a global journey, primarily serving markets across the African, Latin American, and Southeast Asian regions. The firm specializes in a wide array of pharmaceutical products, encompassing everything from injectables and ophthalmics to oral solids and liquids. By focusing on markets that were often overlooked by larger pharmaceutical giants, Caplin Point carved out a niche that allowed it to flourish with minimal competition. The company's business model hinges on leveraging cost-effective manufacturing paired with a deep understanding of diverse regulatory environments, deftly navigating these to establish a loyal customer base amidst underrepresented geographies. The revenue streams of Caplin Point Laboratories are primarily fueled by its ability to adapt product lines to meet the specific needs of each market it serves. This adaptability, combined with a robust distribution network, facilitates the swift movement of goods—ensuring prompt delivery to consumers who rely on its products for basic health needs. Through strategic partnerships and continual investment in research and development, Caplin Point enhances its capacity for innovation, allowing it to advance the quality and range of its pharmaceutical offerings. Furthermore, the company has steadily expanded into regulated markets with its sights set on injectables and has plans for further diversification. This strategic orientation underscores its ambition to transition from a regional powerhouse to a formidable player on the broader global stage.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Caplin Point Laboratories Ltd is 28.9%, which is above its 3-year median of 27%.
Over the last 3 years, Caplin Point Laboratories Ltd’s Net Margin has increased from 24.1% to 28.9%. During this period, it reached a low of 24.1% on Aug 30, 2022 and a high of 28.9% on Oct 30, 2025.